October 3rd Deadline Alert: GPM Reminds Investors of the Upcoming Deadline in the Class Action Lawsuit Against Keryx Pharmace...

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the October 3, 2016 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased or otherwise acquired Keryx Pharmaceuticals, Inc. ("Keryx" or the "Company") (NASDAQ: KERX) securities in the newly expanded Class Period of September 2, 2013 and August 1, 2016, inclusive (the “Class Period”). Keryx investors have October 3, 2016 to file a lead plaintiff motion.

The complaint filed in this lawsuit alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose: (1) that the Company was experiencing production-related difficulties in converting API to finished drug product; (2) that the issue was resulting in decreased production yields of finished drug product; (3) that, as a result, the Company would, and did exhaust its reserve of finished drug product; and (4) that, as a result of the foregoing, Defendants’ statements about Keryx’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

If you purchased or otherwise acquired Keryx shares during the Class Period, you may move the Court no later than October 3, 2016 to request appointment as lead plaintiff. To be a member of the class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [e-mail], or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160927006661/en/

Glancy Prongay & Murray LLP, Los AngelesLesley Portnoy, 310-201-9150 or [e-mail]